Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Efficacy of cognitive rehabilitation in cognition and brain networks: A randomised clinical trial in patients with multiple sclerosis.

NeuroImage. Clinical·2025

Same author

Synthetic MRI in Progressive MS: Associations with Disability.

AJNR. American journal of neuroradiology·2025

Same author

[XVI Post-ECTRIMS Meeting: review of the new developments presented at the 2023 ECTRIMS Congress (II)].

Revista de neurologia·2024

Same author

[XVI Post-ECTRIMS Meeting: review of the new developments presented at the 2023 ECTRIMS Congress (I)].

Revista de neurologia·2024

Same author

[15th Post-ECTRIMS Meeting: a review of the latest developments presented at the 2022 ECTRIMS Congress (Part II)].

Revista de neurologia·2023

Same author

[Revista de Neurologia is celebrating its 50th anniversary].

Revista de neurologia·2023

Search research articles

Related Experiment Video

Updated: Jun 2, 2026

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

[Monoclonal antibodies in [corrected] development in [corrected] multiple sclerosis].

J Sastre-Garriga¹, X Montalban

¹Unitat de Neuroimmunologia Clínica, Centre d'Esclerosi Múltiple de Catalunya (CEM-Cat), Hospital Vall d'Hebron, Barcelona, España.

Neurologia (Barcelona, Spain)

|April 13, 2011

Summary

New monoclonal antibodies show promise as advanced disease-modifying therapies for multiple sclerosis (MS). While efficacy appears high, careful patient monitoring is essential due to the safety profile of these novel MS treatments.

More Related Videos

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

Related Experiment Videos

Last Updated: Jun 2, 2026

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

Area of Science:

Neurology
Immunology
Pharmacology

Background:

Multiple sclerosis (MS) treatment has evolved with new disease-modifying therapies.
Orally administered drugs and monoclonal antibodies represent recent advancements.
Monoclonal antibodies are a distinct class of MS therapeutics.

Purpose of the Study:

To review the safety and efficacy of three monoclonal antibodies for multiple sclerosis.
To discuss alemtuzumab, rituximab/ocrelizumab, and daclizumab based on Phase II trial data.

Main Methods:

Review of published articles and clinical trial databases (ClinicalTrials.gov, EMA, Spanish Medicines Agency).
Focus on Phase II study results for alemtuzumab, rituximab/ocrelizumab, and daclizumab.

Main Results:

Alemtuzumab, rituximab/ocrelizumab, and daclizumab have shown positive results in Phase II trials.
These antibodies represent a potential advancement over existing MS therapies.

Conclusions:

Definitive efficacy and safety require Phase III trial data.
Monoclonal antibodies may offer superior efficacy but necessitate rigorous patient monitoring for risk/benefit assessment.